Pre-Surgical Evaluation video
for AspireSR

How does AspireSR work?

82% of patients with epilepsy experience rapid heart rate with a seizure.

Eighty-two percent (82%) of patients with epilepsy experience rapid heart rate increase associated with a seizure.2

How AspireSR works:

  • Detects rapid heart rate rise

  • Delivers automatic stimulation

  • Has customizable parameters to meet patients' needs

  • Works in conjuction with Normal and Magnet Mode

Learn how AspireSR® works in drug‐resistant epilepsy patients.

In AspireSR clinical trials, over 60% of seizures treated (n=46) ended during auto stimulation.3 For seizures that ended during stimulation (n=28), the closer stimulation was to seizure onset, the shorter the seizure duration.3

See clinical data for AspireSR® in drug‐resistant epilepsy patients.

*Individual study patient example. Results may vary.

Patients in the AspireSR clinical studies experienced seizure cessation, shorter seizures, and improved postictal recovery3

Clinical outcomes observed in AspireSR trials include3:

Learn about clinical outcomes for AspireSR® in drug‐resistant epilepsy patients.
  • Reduced seizure duration
  • Reduced seizure severity
  • Reduced seizure frequency
  • Improved quality of life

AspireSR: Advancing the proven long-term efficacy and safety of VNS Therapy


The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures that are refractory to antiepileptic medications.

Talk to your doctor to find out if VNS Therapy might be right for you.

Safety and Tolerability

AspireSR has demonstrated safety and tolerability comparable to currently available VNS Therapy

Learn about the safety and tolerability of AspireSR®.
  • Proven safe and tolerable, without pharmacological burden

  • No unanticipated adverse effects

  • Well-tolerated surgical implantation

The AutoStim Mode is not recommended for patients being treated for cardiac arrhythmia or with a history of bradycardia.

Important Safety Information
Incidence of adverse events following stimulation (>5%) were dysphonia, convulsion, headache, oropharyngeal pain, depression, dysphagia, dyspnea, dyspnea exertional, stress, and vomiting.

Contact Cyberonics for more information, 800-332-1375


1. Nevalainen O, et al. Neurology. 2014 Nov 18;83(21):1968-1977.
2. Eggleston KS, et al. Seizure. 2014 Aug;23(7):496-505.
3. Data on file, Cyberonics Inc. Houston, TX.